Novo Nordisk reaches primary endpoint in phase III of once-weekly insulin
Novo Nordisk’s phase III study of insulin icodec, a once-weekly treatment for type 2 diabetes, has concluded, and the company reports that its primary goal was achieved.
by marketwire, translated by daniel pedersen
Novo Nordisk has concluded a phase III study, dubbed Onwards 2, of once-weekly insulin icodec, the company has announced in a Thursday press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
